Navigation Links
Cytochroma Announces Positive Comparative Data on CTA018 in Chronic Kidney Disease Model
Date:11/6/2008

CTA018 Confers Therapeutic and Safety Advantages Over Current Therapies

MARKHAM, Ontario, Nov. 6 /PRNewswire/ -- Cytochroma today announced positive comparative data on a novel vitamin D analog, CTA018, at the 2008 Annual Meeting of the American Society of Nephrology (ASN) in Philadelphia. In preclinical models, CTA018 has demonstrated advantages over two marketed vitamin D hormone replacement therapies, calcitriol and paricalcitol (Zemplar(R)), the latter currently being the most widely used therapy for secondary hyperparathyroidism (SHPT) in the United States (U.S.). These data were presented in a poster presentation entitled "The Metabolic Profile of CTA018 Confers Therapeutic and Safety Advantages over Current Therapies in an Adenine-Induced Model of Chronic Kidney Disease (CKD)."

Martin Petkovich, PhD, Cytochroma's Chief Scientific Officer, stated, "CTA018 shows characteristics in a well-accepted preclinical model of uremia which strongly indicate that it will offer clear advantages to CKD patients over currently approved therapies. We look forward to seeing these advantages confirmed in ongoing and future clinical studies with CTA018 Injection."

The newly disclosed data support the following four conclusions regarding CTA018:

(1) CTA018 is a Potent VDR Agonist and CYP24 Inhibitor

CTA018 is a dual action active vitamin D analog. Like currently approved vitamin D therapies for SHPT, CTA018 is a potent activator of the vitamin D receptor (VDR), but unlike current therapies, it is also a potent and specific inhibitor of CYP24, the vitamin D catabolic enzyme. Data presented today at the ASN demonstrate that CTA018 is at least 10 times more effective than calcitriol and paricalcitol in activating the VDR, and over 7 times more effective in inhibiting CYP24 than ketoconazole, one of the most potent CYP24 inhibitors known.

(2) CTA018 has a Short Half-Life in Human Enterocytes

Currently marketed vitamin D hormone
'/>"/>

SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... but your outpatient doctor does not know? Or ... care, but your doctor does not have the ... or incomplete communication from hospitals to outpatient primary ... and lead to hospital readmissions. , However, ... improve hospitals, communication during patient care transitions. Researchers ...
(Date:9/2/2014)... associated with many health risks, including heart disease and ... possible way to mitigate one often-overlooked risk: not buckling ... by Sheldon H. Jacobson, a professor of computer science ... are associated with a decrease in seatbelt usage. However, ... in effect. , "Primary seatbelt laws lead to increased ...
(Date:9/2/2014)... New York (PRWEB) September 02, 2014 With ... is making it easy to create a consistent look or ... physical structure, to the floor you walk on and the ... for all custom reclaimed wood designs. , “We’re excited ... to our product line. It saves time, adds consistency, and ...
(Date:9/2/2014)... Cleveland, Ohio (PRWEB) September 02, 2014 ... Cellulon® Polyurethane technology to reduce discomfort and fatigue by ... flooring. Using an eco-friendly, renewable bio-foam core, these anti-fatigue ... in the USA. According to a study by the ... showing a significant difference in reducing spinal compression and ...
(Date:9/2/2014)... AUGUSTA, Ga. A little white pill may help ... exercise capacity than their peers, even if their lungs ... drug sildenafil marketed as Revatio to treat pulmonary ... as a cocktail of over-the-counter antioxidants will help them ... makes exercise difficult for these patients. , "We ...
Breaking Medicine News(10 mins):Health News:Can data motivate hospital leaders to improve care transitions? 2Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Pioneer Millworks Now Offering Products Beyond Reclaimed Wood Flooring 2Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4
... Wagoner on new data showing first increase in U.S.,teen ... that the,dramatic decrease in teen pregnancy rates in the ... a screeching halt. This unwelcome,development should not come as ... success over the last decade -- the decline in ...
... of,Hematology (ASH), the world,s largest professional society of ... notable,contributions to the genetic understanding of disease. Carlo ... intended to honor an individual,with a distinguished career ... receive the William Dameshek Prize, awarded to an ...
... HEI, Inc. (Nasdaq: HEII ),( http://www.heii.com ) ... with the,Securities and Exchange Commission to voluntarily deregister its ... expects that the,deregistration will be effective after 90 days, ... deregister. As a result of this filing, HEI,s,obligation to ...
... found in household fittings has been found to affect the ... will be required to determine if the presence of this ... the online open access journal BMC Genomics is the first ... profile. , Jose Russo and coworkers from the Fox Chase ...
... A new study in the Annals,of Emergency Medicine ("Increasing ... United States, 1993 to 2003") finds the rate of,elderly ... any,other group., Kenneth L. Noller, MD, President of ... statement about the,study on behalf of the Alliance of ...
... air pollution, especially diesel exhaust , , WEDNESDAY, Dec. 5 ... the health damage done by automotive air pollution, especially ... period of improving air quality in Switzerland, which started ... measurable benefits in lung function for adults as they ...
Cached Medicine News:Health News:Top Scientists to Receive Prestigious Awards From the American Society of Hematology 2Health News:Top Scientists to Receive Prestigious Awards From the American Society of Hematology 3Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 2Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 3Health News:Dramatic Growth Projected in Visits by Elderly Patients to Emergency Departments Underscores Urgency of Medicare Physician Payment Fix 2Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3
(Date:9/2/2014)... , Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® in the ... that BioSpecifics, President, Tom Wegman , will present at ... Rodman & Renshaw 16 th ... ) Tuesday, September 9, 2014 at 9:10 a.m. ...
(Date:9/2/2014)... Sept. 2, 2014  Amgen (NASDAQ: ... of a Marketing Authorization Application (MAA) to ... centralized procedure for talimogene laherparepvec seeking approval ... that is regionally or distantly metastatic. Talimogene laherparepvec ... an intralesional injection that is designed to ...
(Date:9/2/2014)... SAN CARLOS, Calif. , Sept. 2, 2014 /PRNewswire/ ... a leader in synthetic biology, today announced that it ... Sanofi Chimie, a wholly owned subsidiary of Sanofi (EURONEXT: ... an enhanced production process for a specific family of ... manufacturing operations in France . This ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3
... WaferGen Biosystems, Inc. (OTCBB:WGBSE), a leading developer of state-of-the-art ... second quarter ended June 30, 2011."During the second quarter, ... commercialize the SmartChip Real-Time PCR System.  We accomplished that ... placement financing of $30.6 million in equity and debt ...
... RANCHO CORDOVA, Calif., Sept. 12, 2011 ThermoGenesis Corp. (NASDAQ: ... and services that process and store adult stem cells in ... quarter and all of fiscal 2011. For the ... $5.4 million, compared to $7.2 million in the fourth quarter ...
Cached Medicine Technology:WaferGen Reports Second Quarter 2011 Financial Results 2WaferGen Reports Second Quarter 2011 Financial Results 3WaferGen Reports Second Quarter 2011 Financial Results 4WaferGen Reports Second Quarter 2011 Financial Results 5WaferGen Reports Second Quarter 2011 Financial Results 6WaferGen Reports Second Quarter 2011 Financial Results 7WaferGen Reports Second Quarter 2011 Financial Results 8ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 2ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 3ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 4ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 5ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 6
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
... Volk's super ... biomicroscopy lenses. Variable ... Provide unprecedented fundus ... addressing maximum potential ...
Volk indirect lenses. Standard BIO examinations....
... Sanyo MLS-series top-loading autoclaves ... high pressure steam sterilizing ... unit that is particularly ... reliable, energy saving autoclaves ...
Medicine Products: